TD Asset Management Inc Has $108,000 Stake in Immuneering Corporation (NASDAQ:IMRX)

Key Points

• TD Asset Management Inc reduced its holdings in Immuneering Corporation (NASDAQ:IMRX) by 52.9%, selling 79,810 shares and leaving them with approximately 71,066 shares worth $108,000.
• Several institutional investors have increased their positions in Immuneering, with Southport Management L.L.C. growing its stake by 4.9% and XTX Topco Ltd boosting holdings by 177.2% in the fourth quarter.
• Immuneering's stock has seen a consensus rating of "Moderate Buy" from analysts, with a new average target price of $13.25, following recent upgrades from Mizuho and Needham & Company.

TD Asset Management Inc lessened its stake in Immuneering Corporation (NASDAQ:IMRX - Free Report) by 52.9% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 71,066 shares of the company's stock after selling 79,810 shares during the quarter. TD Asset Management Inc owned 0.20% of Immuneering worth $108,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in IMRX. Tang Capital Management LLC acquired a new position in Immuneering during the fourth quarter worth $27,000. Marshall Wace LLP bought a new position in Immuneering in the fourth quarter valued at $47,000. First Manhattan CO. LLC. bought a new position in Immuneering in the fourth quarter valued at $71,000. XTX Topco Ltd grew its position in Immuneering by 177.2% in the fourth quarter. XTX Topco Ltd now owns 32,650 shares of the company's stock valued at $72,000 after purchasing an additional 20,871 shares in the last quarter. Finally, Two Sigma Investments LP grew its position in Immuneering by 25.0% in the fourth quarter. Two Sigma Investments LP now owns 50,557 shares of the company's stock valued at $111,000 after purchasing an additional 10,126 shares in the last quarter. Institutional investors and hedge funds own 67.65% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Oppenheimer decreased their target price on shares of Immuneering from $25.00 to $21.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Needham & Company LLC reaffirmed a "buy" rating and issued a $9.00 target price on shares of Immuneering in a research report on Wednesday, June 18th. Mizuho raised their target price on shares of Immuneering from $8.00 to $10.00 and gave the company an "outperform" rating in a research report on Wednesday, June 18th. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $13.00 target price on shares of Immuneering in a research report on Wednesday, June 18th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, Immuneering presently has an average rating of "Moderate Buy" and a consensus price target of $13.25.

Immuneering Price Performance

NASDAQ IMRX traded down $0.26 during trading on Friday, reaching $3.25. 347,159 shares of the company's stock were exchanged, compared to its average volume of 450,746. The business has a 50 day moving average price of $3.26 and a 200-day moving average price of $2.15. The stock has a market capitalization of $116.97 million, a P/E ratio of -1.66 and a beta of 0.37. Immuneering Corporation has a fifty-two week low of $1.00 and a fifty-two week high of $4.69.

Insider Transactions at Immuneering

In related news, Director Thomas J. Schall acquired 40,485 shares of Immuneering stock in a transaction on Tuesday, June 17th. The stock was purchased at an average cost of $2.21 per share, with a total value of $89,471.85. Following the completion of the transaction, the director directly owned 43,385 shares in the company, valued at $95,880.85. This trade represents a 1,396.03% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Peter Feinberg acquired 25,000 shares of the firm's stock in a transaction on Wednesday, June 18th. The stock was bought at an average price of $2.53 per share, for a total transaction of $63,250.00. Following the completion of the acquisition, the director owned 136,766 shares of the company's stock, valued at approximately $346,017.98. The trade was a 22.37% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders acquired 127,507 shares of company stock worth $334,318. 22.90% of the stock is owned by company insiders.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.